News | September 18, 2009

AHRQ Report Calls Proton Beam Radiation Therapy Promising

September 19, 2009 - Particle beam radiation therapy (PBRT) is safe and may provide effective tumor control, but "there are not enough comparative studies to base an evaluation of the clinical or cost effectiveness of [the technology] compared with other treatments," concluded investigators at the Tufts Medical Center Evidence-based Practice Center in Boston, which did the review for the Agency for Healthcare Research and Quality (AHRQ).

PBRT delivers radiation with electrically charged atomic particles. It is believed to provide superior depth-dose distribution, delivering maximum radiation to the target with minimal impact on surrounding tissue. Seven U.S. centers have PBRT facilities, and the investigators reported at least four more are being built at costs ranging from $100 million to $250 million.

The Tufts investigators conducted a Medline search to identify studies of any design that described clinical outcomes or adverse events in 10 or more patients with cancer who received PBRT. For purposes of the review, the investigators defined charged-particle radiation therapy as irradiation with protons, helium ions, or heaver ions; they explicitly excluded radiation therapy with neutrons or other particles. Conventional radiation therapy was defined as external photon-beam radiation guided by 2D or 3D imaging with or without the use of treatment-planning computers or older technologies and without beam intensity modulation.

Of 243 eligible articles in which charged-particle radiation therapy was used alone or in combination with other interventions for various cancer types, 185 (76%) were retrospective studies and 35 (14%) were prospective single-group trials. Only 8 randomized controlled trials were found; 13 comparative studies were not randomized.

The size of the trials ranged from 10 to 2,645 patients (median, 63). Follow-up ranged from 5 months to more than 10 years in two studies. Three-fourths of the studies assessed adverse events, but established scales were not always used.

Methodologic limitations of the various studies hindered useful comparisons, the authors noted. For example, "typically, studies did not provide detailed information on cancer staging or explicit descriptions of the clinical context," they wrote.

Additionally, when the treatment was used in combination with other therapies, the studies often assessed the treatment strategies as a whole and did not evaluate each specific strategy individually. Inconsistencies in reporting criteria, patient characteristics, and outcome definitions further diluted the value of the data for comparison.

Only three randomized, comparative studies explicitly stated primary outcomes, and no trial was designed to have a sufficiently large sample size or follow-up duration to demonstrate statistically significant differences in overall or cancer-specific survival, according to the report.

The authors wrote: "four trials reported statistically significant differences in various other outcomes...In 3 of 4 trials, the results favored the charged-particle radiation therapy group."

The researchers agreed with previous reviewers that PBRT is a viable alternative to conventional radiation therapy for certain types of cancer, such as head and neck cancer, where risk to critical structures is greater.

For more information: www.ahrq.gov

Related Content

Mevion Receives 510(k) Clearance for Hyperscan Pencil Beam Scanning Proton Therapy
Technology | Proton Therapy | January 04, 2018
Mevion Medical Systems has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the Mevion S250i...
Study Compares Radiosurgery and Whole-Brain Radiation in Lung Cancer Patients With Multiple Brain Metastases
News | Radiation Therapy | January 03, 2018
Although targeted therapies have produced dramatic advances in the ability to control some types of advanced lung...
MEDraysintell Downgrades Proton Therapy Market Projection for 2030
News | Proton Therapy | January 02, 2018
MEDraysintell recently downgraded its projection for proton therapy rooms expected to be operational in 2030 from 1,200...
California US Oncology Network Centers Adopt Xoft Electronic Brachytherapy System for Early-Stage Non-Melanoma Skin Cancer
News | Brachytherapy Systems | January 02, 2018
iCAD Inc. announced that its Xoft Axxent Electronic Brachytherapy (eBx) System is now available at two California-based...
Blue Phantom System Used for Acceptance of First European Varian Halcyon Machine
News | Radiation Therapy | January 02, 2018
IBA (Ion Beam Applications S.A.) announced in November the acceptance and beam model validation of the first Varian...
Study Finds Link Between Breast Cancer Treatments and Cellular Aging Markers
News | Women's Health | January 02, 2018
January 2, 2018 — A new study found women who had received chemotherapy and/or...
ACR Appropriateness Criteria Adds and Revises Topics for December 2017
News | Clinical Decision Support | December 29, 2017
December 29, 2017 — Radiologists can enhance the quality and effectiveness of care with the newest release of the ACR
FDA Clears GammaPod Stereotactic Radiotherapy System for Breast Cancer Treatment
Technology | Stereotactic Body Radiation Therapy (SBRT) | December 22, 2017
The U.S. Food and Drug Administration (FDA) has cleared the new GammaPod noninvasive stereotactic radiotherapy system...
RaySearch Launches RayCare Oncology Information System

Image courtesy of RaySearch Laboratories

Technology | Oncology Information Management Systems (OIMS) | December 22, 2017
RaySearch announced the first release of RayCare, a new oncology information system (OIS) designed to connect the...
RaySearch Releases RayStation 7 Radiotherapy Treatment Planning System
Technology | Treatment Planning | December 19, 2017
RayStation 7, the latest release of RaySearch’s radiation therapy treatment planning system, adds new functionality and...
Overlay Init